biology

Idecabtagene vicleucel

Idecabtagene vicleucel is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Idecabtagene vicleucel rather than just read about it. In short: Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma. The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia).

Key takeaways

Idecabtagene vicleucel belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Idecabtagene vicleucel to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Idecabtagene vicleucel from memory before moving on to harder problems.

Reference excerpt

Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma. The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia). Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. Each dose is customized using a patient's own T-cells, which are a type of white blood cell, that are collected and genetically modified to include a new gene that facilitates targeting and killing myeloma cells, and infused back into the patient. Idecabtagene vicleucel was approved for medical use in the United States in March 2021. It is the first cell-based gene therapy approved by the US Food and Drug Administration for the treatment of multiple myeloma. It was authorized for medical use in the European Union in August 2021.

Medical uses Idecabtagene vicleucel is indicated for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in many bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts. Myeloma can also damage the bones and the kidneys and weaken the immune system. The exact cause of multiple myeloma is unknown. According to the National Cancer Institute, myeloma accounted for approximately 1.8% (32,000) of all new cancer cases in the United States in 2020.

Adverse effects The US prescription label for idecabtagene vicleucel carries a boxed warning for cytokine release syndrome (CRS), neurologic toxicity, hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), and prolonged cytopenia. CRS and HLH/MAS are systemic responses to the activation and proliferation of CAR-T cells causing high fever and flu-like symptoms, and prolonged cytopenia is a drop in the number of a certain blood cell type for an extended period of time. In April 2024, the boxed warning was expanded to include T cell malignancies.

History The safety and efficacy of idecabtagene vicleucel were evaluated in a multi-center study of 127 people with relapsed (myeloma that returns after completion of treatment) and refractory (myeloma that does not respond to treatment) multiple myeloma who received at least three prior lines of antimyeloma therapies; 88% had received four or more prior lines of therapies. Efficacy was evaluated in 100 people who received idecabtagene vicleucel in the dose range of 300 to 460 ×106 CAR-positive T cells. Overall, 72% of people partially or completely responded to the treatment. Of those studied, 28% of people showed complete response—or disappearance of all signs of multiple myeloma—to idecabtagene vicleucel, and 65% of this group remained in complete response to the treatment for at least twelve months.

Society and culture

Legal status Idecabtagene vicleucel was approved for medical use in the United States in March 2021, and in the European Union in August 2021. The US Food and Drug Administration (FDA) granted the application for idecabtagene vicleucel breakthrough therapy and orphan drug designations. The FDA granted approval of Abecma to Celgene Corporation, a Bristol-Myers Squibb Company.

Names Idecabtagene vicleucel is the international nonproprietary name. Idecabtagene vicleucel is sold under the brand name Abecma.

References

Further reading Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. (February 2021). "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma". N Engl J Med. 384 (8): 705–16. doi:10.1056/NEJMoa2024850. hdl:11585/865225. PMID 33626253. S2CID 232048693.{{cite journal}}: CS1 maint: overridden setting (link) Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. (May 2019). "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma". N Engl J Med. 380 (18): 1726–37. doi:10.1056/NEJMoa1817226. PMC 8202968. PMID 31042825.{{cite journal}}: CS1 maint: overridden setting (link)

External links Clinical trial number NCT03361748 for "Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Idecabtagene vicleucel

Start with the simplest possible case. Write down what Idecabtagene vicleucel claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Idecabtagene vicleucel before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Idecabtagene vicleucel ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Idecabtagene vicleucel

In research: Idecabtagene vicleucel appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Idecabtagene vicleucel in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Idecabtagene vicleucel is common in secondary-school and first-year university syllabi. It links to neighbouring topics Approved gene therapies, CAR T-cell therapy, Cancer treatments, so understanding it makes those chapters shorter.
In everyday life: Look for Idecabtagene vicleucel outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Idecabtagene vicleucel in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Idecabtagene vicleucel means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Idecabtagene vicleucel out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Idecabtagene vicleucel in simple terms?

Why does Idecabtagene vicleucel matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Idecabtagene vicleucel?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Idecabtagene vicleucel.